Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 184

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Trial of Minocycline in a Clinically Isolated Syndrome of Multiple Sclerosis

Open access
Metz, Luanne M., Li, David K.B., Traboulsee, Anthony L., Duquette, Pierre, Eliasziw, Misha, Cerchiaro, Graziela, Greenfield, Jamie, Riddehough, Andrew, Yeung, Michael, Kremenchutzky, Marcelo, Vorobeychik, Galina, Freedman, Mark S., Bhan, Virender, Blevins, Gregg, Marriott, James J., Grand’Maison, Francois, Lee, Liesly, Thibault, Manon, Hill, Michael D., Yong, V. Wee·2017·New England Journal of Medicine

Abstract

BACKGROUND: On the basis of encouraging preliminary results, we conducted a randomized, controlled trial to determine whether minocycline reduces the risk of conversion from a first demyelinating event (also known as a clinically isolated syndrome) to multiple sclerosis. METHODS: -weighted MRI]). RESULTS: A total of 142 eligible participants underwent randomization at 12 Canadian multiple sclerosis clinics; 72 participants were assigned to the minocycline group and 70 to the placebo group. The mean age of the participants was 35.8 years, and 68.3% were women. The unadjusted risk of conversion to multiple sclerosis within 6 months after randomization was 61.0% in the placebo group and 33.4% in the minocycline group, a difference of 27.6 percentage points (95% confidence interval [CI], 11.4 to 43.9; P=0.001). After adjustment for the number of enhancing lesions at baseline, the difference in the risk of conversion to multiple sclerosis within 6 months after randomization was 18.5 percentage points (95% CI, 3.7 to 33.3; P=0.01); the unadjusted risk difference was not significant at the 24-month secondary outcome time point (P=0.06). All secondary MRI outcomes favored minocycline over placebo at 6 months but not at 24 months. Trial withdrawals and adverse events of rash, dizziness, and dental discoloration were more frequent among participants who received minocycline than among those who received placebo. CONCLUSIONS: The risk of conversion from a clinically isolated syndrome to multiple sclerosis was significantly lower with minocycline than with placebo over 6 months but not over 24 months. (Funded by the Multiple Sclerosis Society of Canada; ClinicalTrials.gov number, NCT00666887 .).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1608889

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 184

Metadata

Authors
Metz, L. M., Li, D. K. B., Traboulsee, A. L., Duquette, P., Eliasziw, M., Cerchiaro, G., Greenfield, J., Riddehough, A., Yeung, M., Kremenchutzky, M., Vorobeychik, G., Freedman, M. S., Bhan, V., Blevins, G., Marriott, J. J., Grand’Maison, F., Lee, L., Thibault, M., Hill, M. D., & Yong, V. W.
Venue
New England Journal of Medicine
Published
2017-06
Volume
376
Issue
22
Pages
2122-2133
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2619378610
Cited by
184
References
6
FWCI
18.91
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Trial of Minocycline in a Clinically Isolated Syndrome of Multiple Sclerosis. https://app.cochat.ai/papers/10.1056/nejmoa1608889
The paper
Metz, L. M., Li, D. K. B., Traboulsee, A. L., Duquette, P., Eliasziw, M., Cerchiaro, G., Greenfield, J., Riddehough, A., Yeung, M., Kremenchutzky, M., Vorobeychik, G., Freedman, M. S., Bhan, V., Blevins, G., Marriott, J. J., Grand’Maison, F., Lee, L., Thibault, M., Hill, M. D., & Yong, V. W. (2017). Trial of Minocycline in a Clinically Isolated Syndrome of Multiple Sclerosis. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1608889

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.